Hidradenitis Suppurativa Associated With Gamma-Secretase Inhibitor Therapy: A Systematic Review

Abstract

Keywords

gamma-secretase inhibitor hidradenitis suppurativa adverse event

Get full access to this article

View all access options for this article.

References

O’Sullivan Coyne

Woodring

Lee

Chen

Kong

HH.

Hidradenitis suppurativa-like lesions associated with pharmacologic inhibition of gamma-secretase. J Invest Dermatol. 2018;138(4):979-981. doi:10.1016/j.jid.2017.09.051

Frantz

Kirwin

Brahe

Hidradenitis secondary to nirogacestat, a recently approved desmoid tumor medication. JAAD Case Rep. 2024;57:1-2. doi:10.1016/j.jdcr.2024.12.022

Gutierrez

DeClerck

Hsiao

Lee

KH.

New onset hidradenitis suppurativa and eruptive milia associated with gamma secretase inhibitor therapy in a patient with desmoid tumor: a case report. JAAD Case Rep. 2025;63:81-83. doi:10.1016/j.jdcr.2025.05.042

Hansen Tai

Hill

Parvathaneni

Islam

Cohen

SR.

Androgenic hidradenitis suppurativa onset linked to gamma secretase inhibitor. JAAD Case Rep. 2025;67:202-204. doi:10.1016/j.jdcr.2025.10.038

Wendland

Teerlink

Pridgen

, et al. A genome-wide association study of hidradenitis suppurativa from the VA’s Million Veteran Program. medRxiv (Preprint). 2025:2025:25330121. doi:10.1101/2025.06.23.25330121